Invasive Pulmonary Fungal Infection Caused by the Fungus Spiromastix in an Immunosuppressive Patient

Turan, Deniz; Do�an, �zlem; �a�, Yasemin; Aksaray, Sebahat; �zakka�, Fatma; Soysal, Emre

Invasive Pulmonary Fungal Infection Caused by the Fungus Spiromastix in an Immunosuppressive Patient [Haydarpasa Numune Med J]

Haydarpasa Numune Med J. 2021; 61(3): 361-366 | DOI: 10.14744/hnhj.2019.55823

Invasive Pulmonary Fungal Infection Caused by the Fungus Spiromastix in an Immunosuppressive Patient

Deniz Turan¹, �zlem Do�an¹, Yasemin �a�², Sebahat Aksaray¹, Fatma �zakka�³, Emre Soysal³
¹Departman Of Medical Microbiology Laboratuvary, University Of Health Sciences, Haydarpasa Numune Training And Research Hospital, Istanbul, Turkey
²Departman Of Infectious Diseases And Clinical Microbiology, Istanbul Medeniyet University, G�ztepe Training And Research Hospital, Istanbul, Turkey
³Istanbul Provincial Health Directorate, Chairman of Public Hospital Services-2, Central Lab Coordinatorship-2, Istanbul

Invasive fungal infections (IFEs) are significant causes of morbidity and mortality, particularly in patients with hematological malignancies and immune deficiency. The fungus Aspergillus is the most commonly detected cause of IFEs in this patient group, although recent studies have reported rare fungi as the causative agent. We present here the case of an 80-year-old male patient who was undergoing remission induction chemotherapy due to acute myeloid leukemia (AML). The patient developed an invasive pulmonary fungal infection caused by the fungus Spiromastix during therapy with liposomal amphotericin B (LAmB) following posaconazole prophylaxis (POS), and was treated successfully with voriconazole (VOR). There have been two studies to date in literature detailing the isolation of the fungus Spiromastix, although this is the first case report from Turkey.

Keywords: Spiromastix spp., invasive pulmonary fungal infection, antifungal therapy

�mm�ns�presif bir hastada Spiromastix cinsi k�f mantar� ile geli�en invaziv pulmoner mantar enfeksiyonu

Deniz Turan¹, �zlem Do�an¹, Yasemin �a�², Sebahat Aksaray¹, Fatma �zakka�³, Emre Soysal³
¹Haydarpa�a Numune E�itim Ve Ara�t�rma Hastanesi, T�bbi Mikrobiyoloji Laboratuvar�, �stanbul
²�stanbul Medeniyet �niversitesi T�p Fak�ltesi, Enfeksiyon Hastal�klar� Ve Klinik Mikrobiyoloji Ad, �stanbul
³�stanbul �l Sa�l�k M�d�rl��, Kamu Hastane Hizmetleri Ba�kanl��-2, Merkezi Laboratuvar-2, �stanbul

�nvaziv fungal enfeksiyonlar (�FE), �zellikle hematolojik maligniteli ve imm�n yetmezli�i bulunan hastalarda �nemli bir morbidite ve mortalite nedenidir. Bu hasta grubunda �FE etkeni olarak en s�k Aspergillus cinsi k�f mantarlar� saptanmakla birlikte, son y�llarda nadir rastlanan k�flerin de etken olabilece�i �e�itli yay�nlarda bildirilmi�tir. Bu raporda akut miyeloid l�semi (AML) tan�s� ile remisyon ind�ksiyon kemoterapisi alan 80 ya��nda erkek hastada posakonazol (POS) profilaksisini takiben Liposomal Amfoterisin B (LAmB) ile tedavi s�ras�nda, Spiromastix cinsi k�f mantar�na ba�l� geli�en ve vorikonazol (VOR) ile ba�ar�l� bir �ekilde tedavi edilen invaziv pulmoner fungal enfeksiyon olgusu sunulmaktad�r. G�n�m�ze kadar literat�rde Spiromastix cinsi k�f mantar�n�n etken olarak izole edildi�i iki olgu bildirilmi� olup, bizim olgumuzda T�rkiye�den bildirilen ilk olgu olma �zelli�ini ta��maktad�r.

Anahtar Kelimeler: Spiromastix spp., invaziv pulmoner fungal enfeksiyon, antifungal tedavi

Corresponding Author: Deniz Turan, T�rkiye
Manuscript Language: Turkish

CITE

Full Text PDF Download citation RIS EndNote BibTex Medlars Procite Reference Manager Send email to author Similar articles PubMed Google Scholar